1. FRI0367 BCX4208 added to allopurinol increases response rates in patients with GOUT who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial. (23rd January 2014) Authors: Becker, M.A.; Hollister, A.S.; Terkeltaub, R.; Waugh, A.; Flynt, A.; Fitz-Patrick, D.; Sheridan, W. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: Results of a phase 2 24-week blinded safety extension and vaccine challenge study. (23rd January 2014) Authors: Hollister, A.S.; Dobo, S.; Maetzel, A.; Becker, M.A.; Terkeltaub, R.; Fitz-Patrick, D.; Smith, V.; Sheridan, W. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 442 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0495 Examination of Serum Uric Acid (Sua) Lowering and Safety with Extended Treatment with Lesinurad and Allopurinol in Subjects with Gout. (15th July 2016) Authors: Saag, K.G.; Becker, M.A.; Storgard, C.; Fung, M.; Bhakta, N.; Adler, S.; Hu, J.; Bardin, T. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 371 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗